Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian pharmaceutical firm Nuvo Research has entered into a collaboration involving Ferndale Laboratories (Ferndale) and a leading Contract Research Organization (CRO) with significant dermatology experience for the development of two topical dermatology products.
Subscribe to our email newsletter
The new products will be based on Nuvo’s patented Multiplexed Molecular Penetration Enhancer (MMPE) technology.
As part of the deal, Nuvo will use its MMPE technology to formulate two patented topical dermatology products, following which Ferndale along with the CRO, will oversee and fund the formulations’ advancement through Phase II clinical trials.
It is expected that the new product candidates will then be made available for out-licensing.
Licensing revenues such as upfront payments, milestone payments and royalties will be shared by all three parties based on a formula that includes compensation to Nuvo for contributing the patented formulations.
Nuvo chairman and co-CEO Dan Chicoine said this exciting opportunity shows how the company can leverage one of its four proprietary technologies that improves the delivery of active drugs into or through the skin.
"This agreement validates our patented drug delivery platforms and highlights our ability to expand our development product pipeline through strategic collaborations with partners who will fund the costs of clinical development," Chicoine said.
Nuvo’s MMPE technology uses special combinations of molecular penetration enhancers to improve delivery of a given drug into or through the skin.
The company holds US patents that cover formulations using certain combinations of particular molecular penetration enhancers (MPEs) together with active drugs in topical formulations.